Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study | Zendy

Roy Homburg | Zendy; M. L. Hendriks | Zendy; T. E. Konig | Zendy; Richard A. Anderson | Zendy; Adam Balen | Zendy; M. Brincat | Zendy; Tim Child | Zendy; Melanie Davies | Zendy; Thomas D’Hooghe | Zendy; Antonio Rosales | Zendy; Madhurima Rajkhowa | Zendy; R. Rueda-Saenz | Zendy; P. G. A. Hompes | Zendy; Cornelis B. Lambalk | Zendy

Open Access

Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study

Author(s) -

Roy Homburg,

M. L. Hendriks,

T. E. Konig,

Richard A. Anderson,

Adam Balen,

M. Brincat,

Tim Child,

Melanie Davies,

Thomas D’Hooghe,

Antonio Rosales,

Madhurima Rajkhowa,

R. Rueda-Saenz,

P. G. A. Hompes,

Cornelis B. Lambalk

Publication year - 2011

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/der401

Subject(s) - polycystic ovary , anovulation , medicine , clomifene , ovulation induction , gynecology , pregnancy rate , live birth , infertility , randomized controlled trial , pregnancy , confidence interval , ovulation , hormone , biology , insulin , insulin resistance , genetics

Clomifene citrate (CC) is accepted as the first-line method for ovulation induction (OI) in patients with polycystic ovary syndrome (PCOS) associated with infertility owing to anovulation. Low-dose FSH has been reserved for women failing to conceive with CC. In this RCT, we tested the hypothesis that pregnancy rate (PR) and live birth rates (LBR) are higher after OI with low-dose FSH than with CC as first-line treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research